Sana Biotechnology (SANA) Set to Announce Earnings on Thursday

Sana Biotechnology (NASDAQ:SANA) is anticipated to issue its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Sana Biotechnology to announce earnings of ($0.1478) per share for the quarter. Individuals can check the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 4:00 PM ET.

Sana Biotechnology (NASDAQ:SANA) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.02. On average, analysts expect Sana Biotechnology to post ($0.72) EPS for the current fiscal year and ($0.61) EPS for the next fiscal year.

Sana Biotechnology Price Performance

Shares of NASDAQ:SANA opened at $2.63 on Thursday. The company’s 50-day moving average price is $3.09 and its two-hundred day moving average price is $3.43. Sana Biotechnology has a one year low of $2.22 and a one year high of $5.58. The stock has a market capitalization of $787.32 million, a PE ratio of -3.46 and a beta of 2.18.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on SANA shares. Bank of America lowered their target price on Sana Biotechnology from $7.00 to $6.00 and set a “buy” rating on the stock in a research report on Friday, August 14th. TD Cowen raised Sana Biotechnology to a “strong-buy” rating in a research report on Monday, August 24th. Weiss Ratings reissued a “sell (d-)” rating on shares of Sana Biotechnology in a research report on Wednesday, October 21st. Finally, Wall Street Zen downgraded Sana Biotechnology from a “hold” rating to a “sell” rating in a research note on Monday, July 20th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $9.33.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc is a clinical-stage biotechnology company focused on developing engineered cell and gene therapies for serious diseases. The company’s approach is designed to create durable treatments by modifying cells outside or inside the body and using them to replace, repair, or supplement damaged or missing biological functions.

Sana is developing proprietary technologies intended to support the delivery and persistence of therapeutic cells. These include platforms for engineering cells to evade immune-system detection, potentially allowing donor-derived cells to be used without extensive immune suppression, as well as methods for delivering genetic instructions directly to targeted tissues.